Muammer Çelik

Dr. Muammer Çelik

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2022 in Respiratory Medicine and Research
Verified
Journal Article
Closed access
VAVildan Avkan-Oğuz
Vildan Avkan-Oğuz
MÇMuammer Çelik
Muammer Çelik
OEOya Özlem Eren-Kutsoylu
Oya Özlem Eren-Kutsoylu
ANArzu Nazli
Arzu Nazli
YUYasin Levent Uğur
Yasin Levent Uğur
AÖA. Aydan Özkütük
A. Aydan Özkütük

8 January 2020 in Cureus
Verified
Journal Article
Open access
PDF file
VAVildan Avkan-Oğuz
Vildan Avkan-Oğuz
MÇMuammer Çelik
Muammer Çelik
ISIsmail S. Satoglu
Ismail S. Satoglu
MEMahmut Cem Ergon
Mahmut Cem Ergon
AAAhmet Emrah Açan
Ahmet Emrah Açan
Primary cutaneous aspergillosis (PCA) can rarely affect immunocompetent people. There is limited knowledge about the prevalence, diagnosis and management of the disease because there are only case reports or small case series in the literature. For this reason, the diagnosis and treatment of three immunocompetent adult patients diagnosed with PCA were discussed by reviewing the literature. In the current report, in addition to treatment with voriconazole for 8-12 weeks we performed repeated surgical debridement for the treatment of these cases. After two negative tissue cultures, the wounds were either successfully closed primarily or reconstructed using a skin graft. Management of PCA cases will become easier as more reports and further studies of PCA contribute to our shared knowledge. Currently, the most appropriate management approach is to make individualized treatment decisions according to the patients’ clinical features and treatment response which includes several surgical debridement as well as antifungal therapy.

5 November 2024 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
MÇMuammer Çelik
Muammer Çelik
MPMehmet Reşit Polat
Mehmet Reşit Polat
VAVildan Avkan-Oğuz
Vildan Avkan-Oğuz

5 April 2024 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
MÇMuammer Çelik
Muammer Çelik
CBCavid Baba
Cavid Baba
ÇIÇağlar Irmak
Çağlar Irmak
SÖSerkan Özakbaş
Serkan Özakbaş
VAVildan Avkan-Oğuz
Vildan Avkan-Oğuz
Background: The risk of hepatitis B virus (HBV) reactivation remains unclear in people with multiple sclerosis (MS) receiving ocrelizumab. We aimed to assess HBV seroprevalence and reactivation risk in MS patients on ocrelizumab and to evaluate the effectiveness of antiviral prophylaxis against HBV reactivation. Methods: In this single-center, cross-sectional study, 400 people with MS receiving ocrelizumab were screened for HBV at baseline and antiviral prophylaxis was implemented based on serological results. Patients were monitored for HBV reactivation, and outcomes were analyzed. Results: Among 56 (14%) patients who had serology compatible with occult or resolved HBV infection, 49 (85.7%) received antiviral prophylaxis regularly and had no HBV reactivation during the follow-up. Reactivation of HBV occurred in 2 out of 7 (28.6%) patients who did not receive antiviral prophylaxis and in one patient who did not adhere to the prophylaxis regimen. All patients with reactivation had anti-HBs levels below 100 mIU/mL and the median titer was significantly lower than the patients with no HBV reactivation (p = 0.034). Conclusion: This study highlights a 14% anti-HBc positivity, indicating a potential risk for HBV reactivation in people with MS receiving ocrelizumab. This suggests the importance of vigilant monitoring and the implementation of prophylactic measures. Our recommendation emphasizes antiviral prophylaxis, particularly for patients with low anti-HBs, and a pre-emptive strategy for others.

13 June 2022 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
MÇMuammer Çelik
Muammer Çelik
MAMadina Abdullayeva
Madina Abdullayeva
SASema Alp-Çavus
Sema Alp-Çavus
Objective: The incidence and mortality of invasive pneumococcal disease are much higher in people over 65 years compared to the general population. The incidence of the disease and the distribution of serotypes changed with the spread of childhood conjugate pneumococcal vaccines and the use of vaccines in the adult age group. Nasopharyngeal carriage is an important stage in the disease pathogenesis. In this study, we aimed to determine the pneumococcal carriage prevalence and serotype distribution in adults aged ≥ 65 years living in a nursing home. Materials and Methods: The nasopharyngeal swabs were taken from ≥ 65 years old people living in Narlıdere Nursing Home. The specimens were cultured and pneumococci were isolated according to colony appearance, optochin sensitivity and solubility in bile salts. Pneumococcal serotypes were identified using the capsule swelling reaction. Results: Pneumococcus was isolated in 10 of 341 subjects and the pneumococcal carriage prevalence was 2.9%. Advanced age, immunocompromised status and chronic renal failure were associated with pneumococcal carriage. In multivariate model, having immunocompromised status was significantly associated with carriage. Serotypes/serogroups of pneumococci were 7F, 23F, 10, 11, 15. 17, 20 and 33. The 13 valent conjugated pneumococcal vaccine serotype carriage prevalence was 0.6%. Conclusion: Although pneumococcal colonization in older people is uncommon, most of the isolated serotypes are not PCV13 serotypes. The monitoring of pneumococcal serotypes can offer useful information about the circulation of this pathogen among older people and the potential protective effect of pneumococcal vaccines. Keywords: Streptococcus pneumoniae, pneumococcal vaccines, serotyping, nursing homes, aged

25 September 2025 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
MÇMuammer Çelik
Muammer Çelik
UUUlker Uysal
Ulker Uysal
ACAliye Cinar
Aliye Cinar
OAOzlem Akin-Yilmaz
Ozlem Akin-Yilmaz
SSSelda Sahin
Selda Sahin
ZKZiya Kuruuzum
Ziya Kuruuzum
Healthcare-associated infections (HAIs) and antimicrobial resistance (AMR) represent major threats to global health. The global increase in AMR is primarily attributed to unnecessary or inappropriate use of antibiotics in humans and animals. Antibiotics, unlike other drugs, are a valuable resource that requires